Orum Therapeutics is an oncology-focused, private, clinical stage biotech pioneering the development of antibody-enabled, dual-precision targeted protein homeostasis. We leverage our TPD² approach to provide targeted protein degraders, and TPS² approach to provide targeted protein stabilizers for cell-specific delivery to improve patient outcomes. Orum is located in Lexington, MA, USA and Daejeon, South Korea.